Arteriovenous malformations in mice lacking activin receptor-like kinase-1

被引:0
|
作者
Lisa D. Urness
Lise K. Sorensen
Dean Y. Li
机构
[1] Program in Human Molecular Biology & Genetics,Department of Medicine
[2] University of Utah,Department of Oncological Sciences
[3] University of Utah,undefined
[4] Howard Hughes Medical Institute,undefined
[5] University of Utah,undefined
[6] University of Utah,undefined
来源
Nature Genetics | 2000年 / 26卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The mature circulatory system is comprised of two parallel, yet distinct, vascular networks that carry blood to and from the heart. Studies have suggested that endothelial tubes are specified as arteries and veins at the earliest stages of angiogenesis, before the onset of circulation1,2,3,4. To understand the molecular basis for arterial-venous identity, we have focused our studies on a human vascular dysplasia, hereditary haemorrhagic telangiectasia (HHT), wherein arterial and venous beds fail to remain distinct. Genetic studies have demonstrated that HHT can be caused by loss-of-function mutations in the gene encoding activin receptor-like kinase-1 (ACVRL1; ref. 5). ACVRL1 encodes a type I receptor for the TGF-β superfamily of growth factors6,7,8. At the earliest stage of vascular development, mice lacking Acvrl1 develop large shunts between arteries and veins, downregulate arterial Efnb2 and fail to confine intravascular haematopoiesis to arteries. These mice die by mid-gestation with severe arteriovenous malformations resulting from fusion of major arteries and veins. The early loss of anatomical, molecular and functional distinctions between arteries and veins indicates that Acvrl1 is required for developing distinct arterial and venous vascular beds.
引用
收藏
页码:328 / 331
页数:3
相关论文
共 50 条
  • [31] Reduced activin receptor-like kinase 1 activity promotes cardiac fibrosis in heart failure
    Morine, Kevin J.
    Qiao, Xiaoying
    Paruchuri, Vikram
    Aronovitz, Mark J.
    Mackey, Emily E.
    Buiten, Lyanne
    Levine, Jonathan
    Ughreja, Keshan
    Nepali, Prerna
    Blanton, Robert M.
    Oh, S. Paul
    Karas, Richard H.
    Kapur, Navin K.
    CARDIOVASCULAR PATHOLOGY, 2017, 31 : 26 - 33
  • [32] Three novel mutations in the activin receptor-like kinase 1 gene in hereditary hemorrhagic teleangiectasia
    Assis, A
    Ozelo, MC
    Annichino-Bizzacchi, JM
    Costa, FF
    Arruda, VR
    THROMBOSIS AND HAEMOSTASIS, 1999, : 341 - 341
  • [33] Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinomaaEuro
    Simonelli, M.
    Zucali, P.
    Santoro, A.
    Thomas, M. B.
    de Braud, F. G.
    Borghaei, H.
    Berlin, J.
    Denlinger, C. S.
    Noberasco, C.
    Rimassa, L.
    Kim, T. -Y.
    English, P. A.
    Abbattista, A.
    Stampino, C. Gallo
    Carpentieri, M.
    Williams, J. A.
    ANNALS OF ONCOLOGY, 2016, 27 (09) : 1782 - 1787
  • [34] A Phase 2 Study of Dalantercept, an Activin Receptor-Like Kinase-1 Ligand Trap, in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
    Jimeno, Antonio
    Posner, Marshall R.
    Wirth, Lori J.
    Saba, Nabil F.
    Cohen, Roger B.
    Popa, Elizabeta C.
    Argiris, Athanassios
    Grossmann, Kenneth F.
    Sukari, Ammar
    Wilson, Dawn
    Zhang, Xiaosha
    Sun, Jade
    Glasser, Chad
    Attie, Kenneth M.
    Sherman, Matthew L.
    Pandya, Susan S.
    Weiss, Jared
    CANCER, 2016, 122 (23) : 3641 - 3649
  • [35] Enhanced contractility and decreased β-adrenergic receptor kinase-1 in mice lacking endogenous norepinephrine and epinephrine
    Cho, MC
    Rao, M
    Koch, WJ
    Thomas, SA
    Palmiter, RD
    Rockman, HA
    CIRCULATION, 1999, 99 (20) : 2702 - 2707
  • [36] Specific Activin Receptor-Like Kinase 3 Inhibitors Enhance Liver Regeneration
    Tsugawa, Daisuke
    Oya, Yuki
    Masuzaki, Ryota
    Ray, Kevin
    Engers, Darren W.
    Dib, Martin
    Do, Nhue
    Kuramitsu, Kaori
    Ho, Karen
    Frist, Audrey
    Yu, Paul B.
    Bloch, Kenneth D.
    Lindsley, Craig W.
    Hopkins, Corey R.
    Hong, Charles C.
    Karp, Seth J.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2014, 351 (03): : 549 - 558
  • [37] Kaempferol attenuates liver fibrosis by inhibiting activin receptor-like kinase 5
    Xu, Taifu
    Huang, Shan
    Huang, Qianrong
    Ming, Zhiyong
    Wang, Min
    Li, Rongrui
    Zhao, Yinnong
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2019, 23 (09) : 6403 - 6410
  • [38] Activin receptor-like kinase 2 can mediate atrioventricular cushion transformation
    Lai, YT
    Beason, KB
    Brames, GP
    Desgrosellier, JS
    Cleggett, MC
    Shaw, MV
    Brown, CB
    Barnett, JV
    DEVELOPMENTAL BIOLOGY, 2000, 222 (01) : 1 - 11
  • [39] Endothelin-1 Upregulates Activin Receptor-Like Kinase-1 Expression via Gi/RhoA/Sp-1/Rho Kinase Pathways in Human Pulmonary Arterial Endothelial Cells
    Sugimoto, Koichi
    Yokokawa, Tetsuro
    Misaka, Tomofumi
    Kaneshiro, Takashi
    Yamada, Shinya
    Yoshihisa, Akiomi
    Nakazato, Kazuhiko
    Takeishi, Yasuchika
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
  • [40] Targeting heterotopic ossification by inhibiting activin receptor-like kinase 2 function
    Shi, Fuli
    Gao, Jiayu
    Zou, Junrong
    Ying, Ying
    Lin, Hui
    MOLECULAR MEDICINE REPORTS, 2019, 20 (04) : 2979 - 2989